Our Approach

The Challenge and Funding Gap

Glioblastoma is the most aggressive primary brain cancer, with a median survival of just 15 months—a statistic that has seen negligible improvement in decades. Each year, 13,000 new patients in the U.S. face this diagnosis, which imposes immense neurological and emotional burdens on families. The disease’s complexity and invasive growth have historically stalled the development of effective therapies.

Despite the urgent need, private investment in glioblastoma lags far behind other oncology areas. Between 2018 and 2023, glioblastoma-focused biotech attracted just $1.2 billion in venture capital—less than 2% of total oncology investment. The Daniel W. Offit Fund was founded to close this gap by providing the targeted, strategic capital necessary to unlock breakthroughs.

Venture Philanthropy for Impact

The Daniel W. Offit Fund is accelerating breakthroughs across the entire glioblastoma landscape through a high-impact venture philanthropy model. We bridge the gap between discovery and the bedside by:

  • Vetting with Experts: Leveraging a world-class Scientific Advisory Board to identify the most promising science advances in diagnostics, care models, therapeutics and beyond.

  • Funding the Frontiers: Investing in early-stage, "high-risk" concepts, from basic science to novel patient support systems, that traditional funding often overlooks.

  • Scaling Breakthroughs: Providing the capital and strategic mentorship necessary to move advanced academic projects and biotech startups into clinical application.

  • Enhancing the Patient Experience: Supporting innovative clinical care and diagnostic tools that improve quality of life and outcomes for those currently facing a diagnosis.

  • Reinvesting for the Future: Recycling investment returns to create a self-sustaining engine for glioblastoma research and care innovation.

Key Areas of Technical Innovation

We strategically invest in the most promising, cutting-edge frontiers of glioblastoma research and care. Our focus areas include:

  • Next-Generation Therapeutics: Advancing immunotherapies (including CAR-T and vaccines), oncolytic virotherapy, and advanced gene therapies.

  • Precision Medicine & Delivery: Overcoming the blood-brain barrier through targeted drug delivery systems, small molecule inhibitors, and rationally designed combination therapies.

  • Advanced Diagnostics & AI: Utilizing artificial intelligence, liquid biopsies, and advanced imaging for early detection, continuous tumor monitoring, and personalized treatment planning.

  • Innovative Modalities: Funding novel, non-invasive, and radiation-based approaches, including Targeted Alpha Therapy and Tumor Treating Fields.

  • Comprehensive Patient Care: Supporting innovations in clinical care models, caregiver support systems, and quality-of-life initiatives to ensure patients receive holistic, state-of-the-art support throughout their journey.

Building a Collaborative Ecosystem

Conquering glioblastoma requires a unified, cross-sector effort. The Daniel W. Offit Fund bridges the gap between research and clinical application by:

  • Forging Strategic Partnerships: Aligning with leading research institutions, foundations, and biotech industry players to leverage collective expertise and scale resources.

  • Activating Expert Networks: Facilitating high-impact collaborations among basic scientists, translational researchers, clinicians, and entrepreneurs to accelerate breakthroughs.

  • Bridging the Knowledge Gap: Convening specialized meetings and workshops to rapidly disseminate critical findings and overcome clinical bottlenecks.

  • Prioritizing Patient Impact: Partnering with advocacy groups and clinical care programs to ensure our investments target the most urgent, unmet needs of patients and their families.